HRP20211291T1 - Kombinacije i njihove primjene - Google Patents

Kombinacije i njihove primjene Download PDF

Info

Publication number
HRP20211291T1
HRP20211291T1 HRP20211291TT HRP20211291T HRP20211291T1 HR P20211291 T1 HRP20211291 T1 HR P20211291T1 HR P20211291T T HRP20211291T T HR P20211291TT HR P20211291 T HRP20211291 T HR P20211291T HR P20211291 T1 HRP20211291 T1 HR P20211291T1
Authority
HR
Croatia
Prior art keywords
lymphoma
synergistic combination
use according
hodgkin
seq
Prior art date
Application number
HRP20211291TT
Other languages
English (en)
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HRP20211291T1 publication Critical patent/HRP20211291T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Claims (22)

1. Sinergistička kombinacija, naznačena time, da sadrži protutijelo specifično za CD19, pri čemu navedeno protutijelo sadrži regiju HCDR1 sa slijedom SYVMH (SEQ ID NO: 1), regiju HCDR2 sa slijedom NPYNDG (SEQ ID NO: 2), regiju HCDR3 sa slijedom GTYYYGTRVFDY (SEQ ID NO: 3), regiju LCDR1 sa slijedom RSSKSLQNVNGNTYLY (SEQ ID NO: 4), regiju LCDR2 sa slijedom RMSNLNS (SEQ ID NO: 5), i regiju LCDR3 sa slijedom MQHLEYPIT (SEQ ID NO: 6) i Idelalisib za uporabu u liječenju ne-Hodgkinovog limfoma, kronične limfocitne leukemije i/ili akutne limfoblastične leukemije.
2. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da protutijelo sadrži varijabilni teški lanac sa slijedom EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYW GQGTLVTVSS (SEQ ID NO: 10) i varijabilni laki lanac sa slijedom DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).
3. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da protutijelo sadrži konstantnu domenu teškog lanca sa slijedom ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE LLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).
4. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da protutijelo sadrži konstantnu domenu lakog lanca sa slijedom RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).
5. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib formuliraju u različitim farmaceutskim pripravcima.
6. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju odvojeno.
7. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 6, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju fizički odvojeno.
8. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 6, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju vremenski odvojeno.
9. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju zajedno.
10. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se Idelalisib primjenjuje prije davanja protutijela koje je specifično za CD19.
11. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se Idelalisib primjenjuje nakon davanja protutijela koje je specifično za CD19.
12. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju istovremeno.
13. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da se radi o liječenju ne-Hodgkinovog limfoma, pri čemu se opcionalno ne-Hodgkinov limfom bira iz skupine koja se sastoji od folikularnog limfoma, limfoma malih limfocita, limfoma limfnog tkiva vezanog uz sluznicu, limfoma marginalne zone, difuznog limfoma B velikih stanica, Burkittovog limfoma i limfoma plaštenih stanica.
14. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest folikularni limfom.
15. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom malih limfocita.
16. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom limfnog tkiva vezanog uz sluznicu.
17. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom marginalne zone.
18. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest difuzni limfom B velikih stanica.
19. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest Burkittov limfom.
20. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom plaštenih stanica.
21. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačena time, da se radi o liječenju kronične limfocitne leukemije.
22. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačena time, da se radi o liječenju akutne limfoblastične leukemije.
HRP20211291TT 2015-08-21 2021-08-11 Kombinacije i njihove primjene HRP20211291T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15181925 2015-08-21
EP16756997.9A EP3337506B1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof
PCT/EP2016/069571 WO2017032679A1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof

Publications (1)

Publication Number Publication Date
HRP20211291T1 true HRP20211291T1 (hr) 2021-12-10

Family

ID=54010888

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211291TT HRP20211291T1 (hr) 2015-08-21 2021-08-11 Kombinacije i njihove primjene

Country Status (24)

Country Link
US (2) US11224654B2 (hr)
EP (2) EP3337506B1 (hr)
JP (3) JP6862422B2 (hr)
KR (2) KR20180042335A (hr)
CN (2) CN107921129B (hr)
AU (3) AU2016311136B2 (hr)
BR (1) BR112018003263A2 (hr)
CA (1) CA2995738A1 (hr)
CY (1) CY1124706T1 (hr)
DK (1) DK3337506T3 (hr)
ES (1) ES2891336T3 (hr)
HK (1) HK1247122A1 (hr)
HR (1) HRP20211291T1 (hr)
HU (1) HUE056408T2 (hr)
IL (2) IL297057A (hr)
LT (1) LT3337506T (hr)
MX (2) MX2018002241A (hr)
PL (1) PL3337506T3 (hr)
PT (1) PT3337506T (hr)
RS (1) RS62260B1 (hr)
RU (1) RU2767063C2 (hr)
SI (1) SI3337506T1 (hr)
WO (1) WO2017032679A1 (hr)
ZA (1) ZA201801052B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276384A1 (en) 2017-05-31 2019-11-07 Incyte Corporation Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CA3203587A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
ES2402591T3 (es) * 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
DK2493503T4 (da) * 2009-10-27 2021-04-12 Amgen Res Munich Gmbh Doseringsplan for administrering af et cd19xcd3-bispecifikt antistof
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2629801B3 (en) * 2010-10-22 2019-11-27 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20200058583A (ko) 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
HUE058855T2 (hu) 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
US9808753B2 (en) 2013-02-15 2017-11-07 3M Innovative Properties Company System and method for making pleated filter media

Also Published As

Publication number Publication date
EP3954388A1 (en) 2022-02-16
AU2016311136A1 (en) 2018-03-01
MX2022006154A (es) 2022-10-07
IL257345A (en) 2018-03-29
IL257345B (en) 2022-11-01
ZA201801052B (en) 2021-05-26
CN115054697A (zh) 2022-09-16
PT3337506T (pt) 2021-09-24
RU2018107929A (ru) 2019-09-23
JP6862422B2 (ja) 2021-04-21
JP2023093495A (ja) 2023-07-04
RU2018107929A3 (hr) 2020-01-14
US20180228893A1 (en) 2018-08-16
CY1124706T1 (el) 2022-07-22
RU2767063C2 (ru) 2022-03-16
RS62260B1 (sr) 2021-09-30
LT3337506T (lt) 2021-10-11
PL3337506T3 (pl) 2022-01-03
JP2021113194A (ja) 2021-08-05
EP3337506B1 (en) 2021-07-21
AU2024202109A1 (en) 2024-05-02
CN107921129B (zh) 2022-05-27
CN107921129A (zh) 2018-04-17
US20220088197A1 (en) 2022-03-24
HK1247122A1 (zh) 2018-09-21
AU2022202800A1 (en) 2022-05-19
SI3337506T1 (sl) 2021-12-31
MX2018002241A (es) 2018-03-23
KR20240052084A (ko) 2024-04-22
ES2891336T3 (es) 2022-01-27
AU2022202800B2 (en) 2024-01-04
IL257345B2 (en) 2023-03-01
JP2018523685A (ja) 2018-08-23
US11224654B2 (en) 2022-01-18
KR20180042335A (ko) 2018-04-25
CA2995738A1 (en) 2017-03-02
WO2017032679A1 (en) 2017-03-02
IL297057A (en) 2022-12-01
EP3337506A1 (en) 2018-06-27
HUE056408T2 (hu) 2022-02-28
BR112018003263A2 (pt) 2018-09-25
AU2016311136B2 (en) 2022-02-17
CN115054697B (zh) 2024-06-11
DK3337506T3 (da) 2021-09-06

Similar Documents

Publication Publication Date Title
HRP20192100T1 (hr) Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe
HRP20211291T1 (hr) Kombinacije i njihove primjene
HRP20210838T1 (hr) Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
HRP20210945T1 (hr) Formulacije protutijela anti-cd19
HRP20220224T1 (hr) Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
JP2017048208A5 (hr)
JP2019533682A5 (hr)
FI3110440T3 (fi) Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi
HRP20220228T1 (hr) Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
RU2015110981A (ru) Комбинации и их применение
JP2017507954A5 (hr)
RS54655B1 (en) DOSAGE MODE FOR USE OF CD19XCD3 Bispecific Antibody
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
JP2023093495A5 (hr)
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
AR092325A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
PE20201494A1 (es) Anticuerpo anti-pacap
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith